Galectin Therapeutics Inc., of Norcross, Ga., said Providence Portland Medical Center filed an investigational new drug application on Dec. 27 to study GR-MD-02 in combination with immunotherapy Yervoy (ipilimumab, Bristol-Myers Squibb Co.) in a Phase Ib trial in patients with metastatic melanoma.